Paul S. Herendeen
- Shareholder represented: FF Hybrid LP, Flat Footed Series LLC-Fund3 y Mason Capital Master Fund, L.P.
- Position: Director
- Type: Proprietary
- First appointment: 09/12/24 by co-option
- Appointment date: 05/06/2025, appointed by the shareholders FF Hybrid LP, Flat Footed Series LLC-Fund3, GP Recovery Fund LLC, Mason Capital Master Fund, L.P. y Sachem Head LP, who have appointed him in exercise of their right to proportional representation, grouping 35,887,742 shares, representing 8.42% of the share capital with voting rights.
Mr. Paul S. Herendeen is a Board member of Elanco Animal Health, Inc. where he is the Chair of the Finance, Strategy and Oversight Committee. He was the Chairman of Endo, Inc. until its merger with Mallinckrodt in August of 2025.
He served as Advisor to the Chairman and Chief Executive Officer at Bausch Health Companies Inc. Prior to that, he was EVP and CFO of Bausch Health. Before joining Bausch Health, he served as EVP and CFO of Zoetis, Inc. Prior to that time, Mr. Herendeen served as chief financial officer at Warner Chilcott, a specialty pharmaceuticals company. He rejoined Warner Chilcott after four years as EVP and CFO of MedPointe.
Mr. Herendeen also has several years of experience in the finance, investment banking, and public accounting sectors. Previously he worked as a principal investor at Dominion Income Management and Cornerstone Partners. Earlier in his career he held various positions including with the investment banking group of Oppenheimer & Company, the capital markets group of Continental Bank Corporation and, early in his career, as a senior auditor with Arthur Andersen & Company.
On the academic side, he holds a bachelor's degree from Boston College and earned an MBA from the University of Virginia's Darden School of Business.